Merck & Co., Inc. Stock Price Boosted to $170 by Guggenheim

The price objective for Merck & Co., Inc. (NYSE:MRK) has been increased by Guggenheim from $146.00 to $170.00, a boost of $24.00 or about 16.44%.

This move follows similar actions from other analysts in recent weeks, including Argus raising their price target on MRK to $170.00 and giving the stock a 'buy' rating, as well as Daiwa Securities Group upgrading Merck & Co., Inc. from a 'neutral' rating to an 'outperform' rating with a price objective of $143.00.

The company's stock has seen significant growth in recent years, with a 1 year high of $156.92 and a market capitalization of $367.35 billion. Merck & Co., Inc. has also been making strides in the biopharmaceutical industry, with its portfolio spanning multiple therapeutic areas.

In other news, EVP Richard Deluca sold 20,784 shares of the stock on August 10th at an average price of $130.43, while EVP David Williams sold 52,847 shares on August 5th at an average price of $128.77.